ArticleInternational journal of women's health2026
Temporal Trends in Mortality of Female Cancers Among Women and the Impact of COVID-19 in Low- and Middle-Income Countries, 1990-2023: An Age-Period-Cohort Analysis from the Global Burden of Disease Study 2023.
Article in International journal of women's health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Early- versus late-onset mortality trends in breast and female genital cancers in Spain, 1999-2024.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Female cancers-breast cancer (BC), cervical cancer (CC), ovarian cancer (OC), and uterine cancer (UC)-among women disproportionately affect low- and middle-income countries (LMICs). We quantified mortality patterns and disentangled age, period, and cohort drivers using Global Burden of Disease Study 2023 data. Methods: We assessed age-standardized mortality rates (ASMRs) in LMICs-upper-middle-income countries (UMCs), lower-middle-income countries (LMCs), and low-income countries (LCs)-from 1990 to 2023, estimated average annual percent change (AAPC) and post-2020 annual changes. Age-period-cohort analysis was applied to disentangle age, period, and cohort effects. Results: From 1990 to 2023, total deaths from female cancers among women more than doubled in LMICs, increasing from 410,667 to 1,053,147. LMCs overtook UMCs to become the largest contributor in 2023. ASMR did not move in a single direction across LMICs. While ASMRs declined in UMCs (AAPC: -0.77%), they increased in LMCs (AAPC: 0.71%) and LCs (AAPC: 1.40%). After 2020, ASMRs rose in all income groups, with the steepest rise in LCs. BC remained the leading cause of death in UMCs and LMCs, while CC predominated in LCs. Age-period-cohort analysis showed period rate ratios declining in UMCs but increasing in LMCs/LCs. For CC in LMCs/LCs, period rate ratios fluctuated slightly and exhibited a minor uptick in 2019-2023. Cohort rate ratios fell across generations in UMCs but rose in LMCs/LCs. Conclusion: Temporal trends in mortality of female cancers among women in LMICs exhibited stratified patterns rather than uniform improvement: ASMRs declined in UMCs but rose persistently in LMCs and LCs, while absolute deaths increased across all income groups. Distinct subtype-specific trajectories further highlight the need for targeted strategies addressing the unique epidemiological and health system challenges of each cancer. Scaling up screening programs, human papillomavirus vaccination, and access to timely treatment is essential to reverse these trends and achieve equitable reductions in female cancer mortality in LMICs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.